Rare Cancers Act 2026

Commons bill Private Members' Bill (Ballot) 2025-26 Act of Parliament

A Private Members' Bill introduced through the annual ballot, which gives backbench MPs a chance to secure Friday debate time. Ballot bills are the only PMBs with a realistic prospect of becoming law without government support.

Passed โ€” Royal Assent 5 March 2026
Sponsor
Dr Scott Arthur (Labour)
+ 1 co-sponsor
  • Julie Elliott
Introduced
16 October 2024
Royal Assent
5 March 2026
About this bill

A Bill to make provision to incentivise research and investment into the treatment of rare types of cancer; and for connected purposes.

Parliamentary stages

Stages shown in blue link to the debate transcript. Not sure what these stages mean? How Parliament makes laws โ†’

Commons
โœ“ First reading 16 Oct 2024
โœ“ Second reading 14 Mar 2025โ†—
โœ“ Money resolution 30 Jun 2025
โœ“ Committee stage 2 Jul 2025
โœ“ Report stage 11 Jul 2025
โœ“ Third reading 11 Jul 2025
Lords
โœ“ First reading 14 Jul 2025
โœ“ Second reading 16 Jan 2026
โœ“ Order Of Commitment Discharged 11 Feb 2026
โœ“ Third reading 27 Feb 2026
Final stages
โœ“ Royal Assent 5 Mar 2026

Some stage debates occurred before our Hansard archive begins (May 2025). Links marked โ†— go to Parliament's own Hansard for that date.

Parliamentary information from bills.parliament.uk โ†—, licensed under the Open Parliament Licence v3.0. Explanatory Notes extracts are verbatim from Parliament's published documents.

What this bill is about

From the Explanatory Notes (July 2025):

1 This Bill is intended to support research and investment for rare cancers. The Bill uses the definition of a rare disease consistent with that specified in the UK Rare Diseases Framework: a condition which affects less than 1 in 2,000 people. 2 The Bill specifically achieves this by: a. Ensuring the Government publishes a review of the law relating to marketing authorisations for orphan medicinal products that are for the diagnosis, treatment or prevention of cancer. The review must consider regulatory approaches in other countries compared to the UKโ€™s approach. These relevant regulations โ€ฆ
Read the full Explanatory Notes โ†—